The effect of pimozide on CSF norepinephrine in schizophrenia.

No abstract is available for this paper.

• Publication year

  1981

• Venue

  American Journal of Psychiatry

• Publication date

  1981-08-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1176/AJP.138.8.1045PMID 7258379
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Electrophysiologic interactions of antipsychotic drugs with central noradrenergic pathways

  2004cited by this paper
• Schizophrenia: elevated cerebrospinal fluid norepinephrine.

  1980cited by this paper
• Monoamine Mechanisms in Chronic Schizophrenia: Post-Mortem Neurochemical Findings

  1979cited by this paper
• The dopamine hypothesis of schizophrenia revisited.

  1979cited by this paper
• Brain norepinephrine and dopamine in schizophrenia.

  1979cited by this paper
• Platelet monoamine oxidase activity in schizophrenia: a review of the data.

  1979cited by this paper
• Clinical assessment of dopamine receptor blockade.

  1978cited by this paper
• Probenecid-induced norepinephrine elevations in plasma and CSF.

  1978cited by this paper
• Norepinephrine in chronic paranoid schizophrenia: above-normal levels in limbic forebrain.

  1978cited by this paper
• State anxiety, physical activity, and urinary 3-methoxy-4-hydroxyphenethylene glycol excretion.

  1978cited by this paper
• Cerebrospinal fluid norepinephrine in affective illness.

  1978cited by this paper
• Neuroleptic drug interactions with norepinephrine alpha receptor binding sites in rat brain.

  1977cited by this paper
• Norepinephrine and 3-methoxy-4-hydroxyphenyl glycol gradients in human cerebrospinal fluid.

  1977cited by this paper
• Interactions of antipsychotic drugs with norepinephrine and cerebellar neuronal circuitry: implications for the psychobiology of psychosis.

  1977cited by this paper
• A new major projection from locus coeruleus: the main source of noradrenergic nerve terminals in the ventral and dorsal columns of the spinal cord.

  1977cited by this paper
• Effect of chlorpromazine treatment on monoamine metabolite levels in cerebrospinal fluid of psychotic patients

  1977cited by this paper
• Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry.

  1976cited by this paper
• The noradrenergic cyclic AMP generating system in the limbic forebrain: pharmacological characterization in vitro and possible role of limbic noradrenergic mechanisms in the mode of action of antipsychotics.

  1976cited by this paper
• Schizophrenia: A theory

  1976cited by this paper
• Noradrenergic influence on the stereotyped behaviour induced by amphetamine, phenethylamine and apomorphine

  1976cited by this paper
• Interaction of beta-phenethylamine with dopamine and noradrenaline in the central nervous system of the rat.

  1976cited by this paper
• The dopamine hypothesis of schizophrenia: a review.

  1976cited by this paper
• Norepinephrine in cerebrospinal fluid.

  1976cited by this paper
• Blockade by pimozide of a noradrenaline sensitive adenylate cyclase in the limbic forebrain: possible role of limbic noradrenergic mechanisms in the mode of action of antipsychotics

  1975cited by this paper
• Dopamine beta-hydroxylase activity in brains of chronic schizophrenic patients.

  1975cited by this paper
• Central noradrenergic function in man: vanillylmandelic acid in CSF.

  1975cited by this paper
• Cerebrospinal fluid amine metabolites in acute schizophrenia.

  1975cited by this paper
• Modification of the receptor component of adenylate cyclase in the rat brain by phenothiazine derivatives.

  1974cited by this paper
• Dopamine-sensitive adenylate cyclase in mammalian brain: a possible site of action of antipsychotic drugs.

  1974cited by this paper
• Cerebrospinal fluid amine metabolites in affective illness: the probenecid technique.

  1973cited by this paper
• Effect of neuroleptics on endogenous norepinephrine in rat brain.

  1973cited by this paper
• Psychomotor activity and cerebrospinal fluid amine metabolites in affective illness.

  1973cited by this paper
• Dopamine-beta-hydroxylase deficits in the brains of schizophrenic patients.

  1973cited by this paper
• Possible Etiology of Schizophrenia: Progressive Damage to the Noradrenergic Reward System by 6-Hydroxydopamine

  1971cited by this paper
• Stereotaxic mapping of the monoamine pathways in the rat brain.

  1971cited by this paper
• Receptor activity and turnover of dopamine and noradrenaline after neuroleptics.

  1970cited by this paper
• Biogenic amines and the states of sleep.

  1969cited by this paper
• Norepinephrine in depressive reactions. A review.

  1965cited by this paper
• Methods for reliable longitudinal observation of behavior.

  1963cited by this paper

• Haloperidol - norepinephrine synergy in stimulation of vacuous chewing movements in rats: Enhancement by nicotine.

  2025cites this paper
• Biomarkers in the cerebrospinal fluid of patients with psychotic disorders compared to healthy controls: a systematic review and meta-analysis

  2023cites this paper
• Psychiatric symptoms of noradrenergic dysfunction: A pathophysiological view

  2014cites this paper
• Iodoreboxetine : the development of a novel SPECT brain imaging tracer for the noradrenaline transporter

  2013cites this paper
• Psychotic Continuum

  2010cites this paper
• The locus coeruleus in schizophrenia: a postmortem study of noradrenergic neurones

  2005cites this paper
• Effect of adjuvant reserpine treatment on catecholamine metabolism in schizophrenic patients under long-term neuroleptic treatment

  2005cites this paper
• Decrease in dopamine, its metabolites and noradrenaline in cerebrospinal fluid of schizophrenic patients after withdrawal of long-term neuroleptic treatment

  2004cites this paper
• Proposal for a noradrenaline hypothesis of schizophrenia.

  2004cites this paper
• Neuroendocrine effects of clonidine in chronic schizophrenic patients under long-term neuroleptic therapy and after drug withdrawal: Relations to psychopathology

  2004cites this paper
• Effects of pharmacological doses of 2-deoxyglucose on plasma catecholamines and glucose levels in patients with schizophrenia

  2004cites this paper
• Hypersensitivity to d-amphetamine several years after early social deprivation in rhesus monkeys

  2004cites this paper
• Relationship between plasma concentration and arousal in normal subjects after single oral and parenteral doses of melperone, a butyrophenone neuroleptic

  2004cites this paper
• +-Noradrenergic effects on ERP and behavioral indices of auditory information processing

  2003cites this paper
• Alpha2-noradrenergic effects on ERP and behavioral indices of auditory information processing.

  2002cites this paper
• Noradrenergic Pathology in Psychiatric Disorders: Postmortem Studies

  2001cites this paper
• Brain Noradrenergic Receptors in Major Depression and Schizophrenia

  1999cites this paper
• First-episode neuroleptic-free schizophrenics: concentrations of monoamines and their metabolites in plasma and their correlations with clinical responses to haloperidol treatment.

  1997cites this paper
• (32-Receptor Density on Mononuclear Blood Patients Suffering from Neuroleptic-Induced Akathisia (NIA) Cells in

  1996cites this paper
• β2-receptor density on mononuclear blood cells in patients suffering from neuroleptic-induced akathisia (NIA)

  1996cites this paper
• Adjunctive nadolol in the treatment of acutely aggressive schizophrenic patients.

  1996cites this paper
• Predicting haloperidol treatment response in chronic schizophrenia.

  1996cites this paper
• Biological predictors of antipsychotic treatment response

  1996cites this paper
• Biochemical Heterogeneity in Schizophrenia: Implications and Research Strategies of the State Dependency Model

  1995cites this paper
• Possible noradrenergic dysfunction in schizophrenia.

  1994cites this paper
• The Effect of Clozapine on Plasma Norepinephrine: Relationship to Clinical Efficacy

  1994cites this paper
• L-dopa helps positive but not negative features of neuroleptic-insensitive chronic schizophrenia

  1994cites this paper
• Biochemical findings of negative symptoms in schizophrenia and their putative relevance to pharmacologic treatment. A review.

  1994cites this paper
• Studies of Catecholamine Metabolism in Schizophrenia/Psychosis-I

  1993cites this paper
• Attenuation of haloperidol-induced catalepsy by noradrenaline and L-threo-DOPS

  1993cites this paper
• Acute effects of neuroleptics on unmedicated schizophrenic patients and controls.

  1993cites this paper
• Gating and habituation of the startle reflex in schizophrenic patients.

  1992cites this paper
• Explorations of Dopamine and Noradrenaline Activity and Negative Symptoms in Schizophrenia: Concepts and Controversies

  1991cites this paper
• The biochemical basis of relapse and drug response in schizophrenia: review and hypothesis

  1991cites this paper
• The biochemical basis of relapse and drug response in schizophrenia: review and hypothesis.

  1991cites this paper
• The role of pimozide in clinical psychiatry: a review.

  1991cites this paper
• Recent concepts in clinical psychiatry: drug treatment in schizophrenia.

  1991cites this paper
• Dopamine and norepinephrine activity in schizophrenia. An integrative perspective.

  1991cites this paper
• Plasma norepinephrine in chronic schizophrenia.

  1990cites this paper
• Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychosis. Implications for regional brain dysfunction in schizophrenia.

  1990cites this paper
• Plasma catecholamine metabolites in schizophrenics: evidence for the two-subtype concept.

  1990cites this paper
• Factors associated with increased noradrenaline levels in schizophrenic patients.

  1990cites this paper
• Are Biochemical Markers for Treatment‐Resistant Schizophrenia State Dependent or Traits?

  1990cites this paper
• Norepinephrine in acute exacerbations of chronic schizophrenia. Negative symptoms revisited.

  1990cites this paper
• Biogenic amines and their metabolites in body fluids of normal, psychiatric and neurological subjects.

  1989cites this paper
• Clonidine treatment of schizophrenia: can we predict treatment response?

  1989cites this paper
• Schizophrenia: Can We Predict

  1989cites this paper
• CSF norepinephrine in schizophrenia is elevated prior to relapse after haloperidol withdrawal.

  1989cites this paper
• Possible increase of dopamine-beta-hydroxylase activity in the locus ceruleus of paranoid schizophrenic patients: a preliminary post-mortem study.

  1989cites this paper
• Current Biological Research in Schizophrenia

  1989cites this paper
• Dextro-amphetamine diminishes negative symptoms in schizophrenia.

  1988cites this paper
• Schizophrenia: instability in norepinephrine, serotonin, and gamma-aminobutyric acid systems.

  1988cites this paper
• Schizophrenia: Instability in Norepinephrine, Serotonin, and γ-Aminobutyric Acid Systems

  1988cites this paper
• Noradrenaline, psychotic decompensation, and drug response in schizophrenia

  1987cites this paper
• Noradrenergic function in schizophrenia.

  1987cites this paper
• Congenital dopamine-beta-hydroxylase deficiency. A novel orthostatic syndrome.

  1987cites this paper
• Neurochemical Findings in the Cerebrospinal Fluid of Schizophrenic Patients with Tardive Dyskinesia and Neuroleptic‐Induced Parkinsonism

  1986cites this paper
• Brain noradrenaline and schizophrenia.

  1986cites this paper
• Biological Studies of the Nosology of the Major Psychoses: A Status Report on the Schizoaffective Disorders

  1986cites this paper
• Schizoaffective Psychoses

  1986cites this paper
• Cerebrospinal fluid studies of monoamine metabolism in schizophrenia.

  1986cites this paper
• Chronic haloperidol inactivates brain noradrenergic neurons.

  1985cites this paper
• Relationship between CSF noradrenaline levels, C‐EEG indicators of activation and psychosis ratings in drug‐free schizophrenic patients

  1985cites this paper
• Are there state-dependent markers in schizophrenia?

  1985cites this paper
• Pathochemical Markers in Major Psychoses

  1985cites this paper
• CSF Studies in Schizophrenia: A Multidimensional Approach

  1985cites this paper
• Pathological Neurochemistry of Cerebrospinal Fluid

  1985cites this paper
• Neurochemical Aspects of Schizophrenia

  1985cites this paper
• Dopamin und Noradrenalin im Liquor cerebrospinalis Schizophrener

  1984cites this paper
• Catecholamines and their receptors in blood: evidence for alterations in schizophrenia.

  1984cites this paper
• Noradrenaline and schizophrenia

  1984cites this paper
• Elevated Cerebrospinal Fluid Noradrenaline in Tardive Dyskinesia

  1984cites this paper
• Impaired noradrenergic transmission in schizophrenia?

  1984cites this paper
• Biological studies of schizoaffective disorders.

  1984influential citation
• Neurotoxic action of kainic acid.

  1983cites this paper
• The Use of Beta‐Adrenergic Blocking Agents in Anxiety Disorders and Schizophrenia

  1983cites this paper
• Schizophrenia: Some Current Neurochemical Approaches

  1983cites this paper
• Clonidine‐induced growth hormone secretion in chronic schizophrenia

  1983cites this paper
• Neurophysiological studies of sensory gating in mania: comparison with schizophrenia.

  1983cites this paper
• Reliability of norepinephrine and major monoamine metabolite measurements in CSF of schizophrenic patients.

  1983cites this paper
• Neuropharmacology: Pathophysiology of schizophrenia — causal role for dopamine or noradrenaline? (reply)

  1983cites this paper
• Plasma noradrenaline and clinical psychopathology in schizophrenia. A correlation analysis.

  1983cites this paper
• Biochemical studies in schizophrenia.

  1983cites this paper
• Dopamine and noradrenalin in the cerebrospinal fluid of schizophrenic patients.

  1983cites this paper
• alpha-Adrenergic receptor function in schizophrenia. Receptor number, cyclic adenosine monophosphate production, adenylate cyclase activity, and effect of drugs.

  1983cites this paper
• CSF dopamine beta-hydroxylase in schizophrenia.

  1983cites this paper
• CSF Dopamine β-Hydroxylase in Schizophrenia: Low Activity Associated With Good Prognosis and Good Response to Neuroleptic Treatment

  1983cites this paper
• The Use of Beta‐Adrenergic Blocking Agents in Anxiety Disorders and Schizophrenia

  1983cites this paper
• Schizophrenia: Some Current Neurochemical Approaches

  1983cites this paper
• Neurotoxic action of kainic acid.

  1983cites this paper
• Plasma Norepinephrine and Dopamine-β-Hydroxylase Activity in Schizophrenia

  1982cites this paper
• Plasma norepinephrine and dopamine-beta-hydroxylase activity in schizophrenia.

  1982cites this paper
• d-Amphetamine-induced heterogeneous changes in psychotic behavior in schizophrenia.

  1982cites this paper
• Schizophrenia: dopamine beta-hydroxylase activity and treatment response.

  1982cites this paper
• Impaired presynaptic regulation of norepinephrine in schizophrenia. Effects of clonidine in schizophrenic patients and normal controls.

  1982cites this paper
• Long-term pimozide pretreatment differentially affects behavioral responses to dextroamphetamine in schizophrenia. Further exploration of the dopamine hypothesis of schizophrenia.

  1982cites this paper
• Prediction of early relapse after pimozide discontinuation by response to d-amphetamine during pimozide treatment.

  1982cites this paper
• Brain catecholamines in schizophrenia — a good case for noradrenaline

  1982cites this paper
• Increased noradrenaline levels in CSF and plasma of schizophrenic patients.

  1982cites this paper
• Selective effects of phenylethylamine on central catecholamines: a comparative study with amphetamine.

  1982cites this paper